Piper Jaffray Companies restated their buy rating on shares of Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) in a research note issued to investors on Tuesday morning. They currently have a $54.00 price objective on the stock.

A number of other research analysts have also recently weighed in on the stock. William Blair started coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set an outperform rating and a $46.00 price objective for the company. Barclays PLC started coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set an overweight rating and a $30.00 price objective for the company. Zacks Investment Research raised shares of Biohaven Pharmaceutical Holding Co from a sell rating to a hold rating in a research note on Monday, August 28th. Morgan Stanley started coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Wednesday, May 31st. They set an overweight rating for the company. Finally, Needham & Company LLC started coverage on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, May 30th. They set a buy rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $43.25.

Shares of Biohaven Pharmaceutical Holding Co (BHVN) traded down 0.19% on Tuesday, hitting $37.75. The stock had a trading volume of 146,664 shares. Biohaven Pharmaceutical Holding Co has a one year low of $17.00 and a one year high of $38.86. The company’s 50 day moving average is $30.68 and its 200 day moving average is $26.34. The stock’s market cap is $1.36 billion.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/15/biohaven-pharmaceutical-holding-cos-bhvn-buy-rating-reiterated-at-piper-jaffray-companies.html.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.